NL-OMON23575尚未招募不适用
Optimizing endoxifen concentration through the induction of CYP3A4, CYP2C and CYP2D6 mediated tamoxifen metabolism.
Erasmus Medical Center - Daniel den Hoed Kliniek, afdeling Interne Oncologie0 个研究点目标入组 12 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 12
研究概览
简要总结
Binkhorst et al. Individualization of tamoxifen treatment for breast carcinoma. Clin Pharmacol Ther. 2012;92(1):62-7
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Histological or cytological confirmed diagnosis of breast cancer, for which treatment with tamoxifen monotherapy is indicated;
- •2. Use of tamoxifen monotherapy for at least 4 weeks (to guarantee steady-state) and willing to continue the treatment until the end of the study;
排除标准
- •1. Pregnant or lactating patients;
- •2. Impossibility to take oral drugs;
研究者
相似试验
已完成
不适用
Optimizing endoxifen concentration through the induction of CYP3A4, CYP2C and CYP2D6 mediated tamoxifen metabolism10006291Breast cancerNL-OMON38337Erasmus MC, Universitair Medisch Centrum Rotterdam12
已完成
不适用
Clinical pharmacology of tamoxifen in breast cancer patientsPersonal history of malignant neoplasm of breastZ85.3RBR-7tqc7kFaculdade de Ciências Farmacêuticas de Ribeirão Preto
进行中（未招募）
不适用
Optimizing tamoxifen therapy through the induction of CYP3A4, CYP2C and CYP2D6 mediated metabolism - Induction of tamoxifen metabolismMedDRA version: 12.1Level: LLTClassification code 10006187Term: Breast cancerBreast cancerEUCTR2010-023776-52-NL12
已完成
不适用
Study of Tamoxifen Dose Escalation in Breast Cancer Patients With CYP2D6 PolymorphismsBreast CancerCYP2D6 PolymorphismNCT01075802Western Sydney Local Health District121
已完成
4 期
Pharmacology of Adjuvant Hormonotherapy in Breast CancerHormono-depending Adjuvant Breast CancerNCT01127295Institut Claudius Regaud2,000